Leveraging Community Setting Multidisciplinary Care in Pancreatic Cancer

Commentary
Video

Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.

Mehmet Sitki Copur, MD, FACP, spoke with CancerNetwork® during Pancreatic Cancer Awareness Month about the importance of multidisciplinary collaboration to improve patient outcomes in the pancreatic cancer field, especially among those who are involved in community practices.

According to Copur, a medical director of Oncology and adjunct professor of Medical Oncology/Hematology at the University of Nebraska Medical Center, a medical oncologist/hematologist at Morrison Cancer Center of Mary Lanning Healthcare, and gastrointestinal editorial advisory board member for the journal ONCOLOGY, it is crucial to involve team members such as the surgical oncologist, medical oncologist, radiation oncologist, and pathologist when treating patients with pancreatic cancer. He also emphasized the use of next-generation sequencing and genetic consultation among patients to complement any treatment strategies for those with pancreatic cancer.

Transcript:

As far as the physicians who practice in the community setting—not necessarily an academic [center]—one big thing I would recommend is in every specialty and every cancer we treat, multidisciplinary involvement is the very first big principle. We have pancreas transplant surgeons at the University of Nebraska who come and hold clinics in my community practice.When you see a patient, the very first thing [to do is] make sure the surgical oncologist, medical oncologist, radiation oncologist, the pathologist, and your basic science [personnel are with you], even if you are in the community. Now, there is the luxury of sending next-generation sequencing to the companies. You don’t have to have the basic science lab. So, the main tenant is that every single patient should have multidisciplinary conditions, pathology, and the basic science of next-generation sequencing.

Genetic consultation is approved by insurance companies. You have to get genetic counseling regardless [for any] patient in your judgment who has a family history that you picked up or not. Make sure you make a referral to a genetic counselor, which would complement your next-generation sequencing on the tumor tissue. The genetic counselor will order germline mutation testing. In real life, if I order it as a physician, they may not necessarily approve it, but if a genetic counselor orders it, that goes through. That would be a huge compliment to start treating your patient.

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Related Content